各种靶向药和化疗药物的说明书

老马兄很好，很好

% V; z; [% {& T7 y+ c: A/ {: U健择（吉西他滨）+顺铂+阿瓦斯汀
Gemzar +Cisplatin + Avastin
8 v% a$ v8 m3 I* bhttp://annonc.oxfordjournals.org/content/21/9/1804.full
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
0 q0 D4 @) L% c  I( kPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
2 s% Y9 J. j8 `5 q Cisplatin Gemzar Avastin.PDF (329.84 KB, 下载次数: 923)

2013-3-13 13:39 上传

点击文件名下载附件

/ V, p- }! K7 Y3 X8 ^华为网盘附件：
【华为网盘】ava.JPG

这个很实用，很好
) c+ C( ]7 k0 o$ a' Z3 f5 r谢谢

知识很全,谢谢老马提供

论坛里有用信息真多，努力学习中…
" n3 o% j4 r+ g0 Q6 J) o: n% M# L; H
谢谢老马，谢谢大家！

有没有每个肿瘤的用药组合推荐啊？

收藏了谢谢老马。

此帖必火

老马整理的太好了~~感谢啊！